Home » Newsletters » The Carlat Addiction Treatment Report

The Carlat Addiction Treatment Report

Substance-Induced Psychiatric Disorders (April/May/June) | 2023

View Archived Issues

Learning Objectives,Substance-Induced Depression: Diagnosis and Treatment, CATR, Apr/May/June 2023

April 1, 2023

After reading these articles, you should be able to…

Naltrexone: A Jack of All Trades?

April 1, 2023

Julio Cesar Nunes, MD

Naltrexone was once hailed as a treatment for all addictive disorders. While the hype has not entirely panned out, it still holds an important place in our armamentarium of addiction treatments. Here, we review the evidence for its use and provide prescribing recommendations.

Substance-Induced Depression: Diagnosis and Treatment

April 1, 2023

Bryan K. Tolliver, MD, PhD

Dr. Tolliver gives us a framework to understand the relation between depression, substance use, and substance-induced mood disorders.

Recognizing and Treating Substance-Induced Psychosis

April 1, 2023

David Beckmann, MD, MPH

Clinical pearls on how to assess and treat substance-induced psychosis when you come across them in your clinic.

Gabapentin: A Double-Edged Sword

April 1, 2023

Noah Capurso, MD and Shram Shukla, MD

Gabapentin has become one of the most widely prescribed medications in America. At the same time, concerns have emerged about its association with opioid overdose deaths. In this article, we review the data behind gabapentin treatment: when it should be used, how to use it, and when it should be avoided.

Methamphetamines and Opioid-Related Overdose Risk

April 1, 2023

Peter J. Farago, MD.

Researchers provide a detailed glimpse into the chaotic state of the illicit opioid supply and show that the potentially dangerous misconception that methamphetamines can be used as an opioid overdose reversal agent is widespread.

Are Higher-Potency Cannabis Products Riskier for Mental Illness?

April 1, 2023

Deepti Anbarasan, MD and John Wang, MD

In recent years, cannabis with widely varying THC concentrations has become available. But is there a link between how much THC a cannabis product contains and its risk of adverse effects. Researchers here add to the mounting evidence that the answer is likely yes.